Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

arting and look forward to continued involvement with this novel approach for the treatment of Fabry disease."

Amigal U.S. Registration Phase 3 Trial Design

The Phase 3 trial will evaluate the efficacy, safety and pharmacodynamics of Amigal in males and females with Fabry disease. This trial will consist of a six-month double-blind, randomized, placebo-controlled treatment stage and will enroll approximately 60 subjects who are naive to enzyme replacement therapy (ERT) or who have not received ERT for at least six months prior to the start of treatment with Amigal. The Amigal treatment arm dose and regimen will be 150 mg every other day.

The primary endpoint will be the change in the amount of kidney interstitial capillary GL-3 as measured in kidney biopsies using histology. Secondary endpoints will include safety and tolerability, kidney GL-3 as measured in urine, and an assessment of renal function (including glomerular filtration rate (GFR) and 24-hour urine protein).

Additionally, the FDA and Amicus reached agreement on an improved methodology for the histological evaluation of GL-3 in the kidney biopsies. An analysis of the Phase 2 and Phase 2 extension study biopsies using the improved methodology demonstrated that all of the evaluable baseline samples had detectable interstitial capillary GL-3 and that reductions were observed in 8 of the 9 responders.

According to Laura Barisoni, MD, Assistant Professor in Pathology and Medicine, Director, Nephropathology Service, Department of Pathology, New York University School of Medicine, "The Phase 2 data using the improved methodology for histological evaluation of GL-3 in kidney biopsies were very encouraging and provide added confidence in the planned Phase 3 study."

It is expected that approximately 30 clinical sites worldwide will participate in this tria
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... CAPE TOWN, South Africa , Jan. 23, 2015 ... and distributor of personal protective equipment for all forms ... include the flagship Leatt-Brace® neck brace, announced today that ... minicross racing federation, now requires all riders to wear ...
(Date:1/23/2015)... , Jan. 23, 2015 Gem Pharmaceuticals announced today ... been enrolled into the Company,s Phase 2 clinical trial. ... of Gem,s lead compound, GPX-150 (an investigational medication), in ... metastatic disease. Logo - http://photos.prnewswire.com/prnh/20150123/170966LOGO ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
Breaking Medicine Technology:Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Gem Pharmaceuticals Announces Enrollment of Initial Patients in its Phase 2 Clinical Trial to Assess the Efficacy and Safety of GPX-150 in Sarcoma Patients 2ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2
... Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) disclosed ... Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will ... Exposition of the American Society of Nephrology (ASN). Dr. ... Director of Nephrology at the Fortis Hospital in New ...
... , MARIETTA, Ga., Oct. 15 Solvay Pharmaceuticals, Inc. ... Delayed-Release Capsules significantly improves a key measure of fat ... pancreatic insufficiency (EPI) due to cystic fibrosis (CF). EPI ... production and/or secretion of pancreatic enzymes that are necessary ...
Cached Medicine Technology:Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 2Aethlon Medical Announces Presentation of Hepatitis-C (HCV) Clinical Data at 42nd Annual American Society of Nephrology (ASN) Conference 3CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 2CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 3CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 4CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 5CREON(R) (pancrelipase) Delayed-Release Capsules Improves Absorption of Fat in Young Children With Cystic Fibrosis 6
(Date:1/23/2015)... Hastings and Hastings, a law firm in Arizona that focuses ... representation client review requests for slip and fall accidents in ... the number of slip and fall related accidents that happen ... that said, a large number of injury victims are requesting ... Hastings and Hastings is a personal injury firm in Arizona ...
(Date:1/22/2015)... LunaDress, with its top dressmaking technologies, has ... the business is showing its latest designs of wedding dresses ... to the company’s CEO, all the fresh new products are ... discounts, up to 80% off. All the clothes from LunaDress ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ ... Alliance (PPHA). The PPHA's passion for others' well-being and ... greats, treated for obstructive sleep apnea (OSA) has propelled them ... in the valley. The most recent plans for an event ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
... law, pledges to, fight for consumers, rights ... ... SEATTLE, March 3 RealSelf.com today filed an ... Trademark,Infringement Complaint, denying Lifestyle Lift,s claims and also responding,with ...
... Wash. and LOS ANGELES, March 3 For the ... inc.,(Nasdaq: DSCM ), has enlisted Los Angeles-based women,s ... doubles as a cosmetic case or,fashionable clutch. Customers receive ... product samples from today,s top prestige beauty,brands with a ...
... Using a new tool designed to measure a womans ... the sexual transmission of HIV), researchers at The Miriam Hospital ... methods in the past, and those with casual sexual partners ... peers. , Although a safe and effective microbicide has ...
... Featuring Emmy award-winning composer, Yale professor and African,women,s ... Malkin, Emmy,award-winning composer, together with poet Kim Rosen, ... Conference in Pittsburgh at,the Westin Convention Center on ... health will be the conference focus. "Spiritual healing ...
... video and information sharing ... ... release of the next phase on Beta site icyou ( http://www.icyou.com ... health video community provides the ability to post and,search healthcare videos, ...
... long agreed that girls have superior language abilities than boys, ... that may account for their differences. , For the ... Northwestern University and the University of Haifa show both that ... girls than in boys during language tasks, and that boys ...
Cached Medicine News:Health News:RealSelf.com Denies Lifestyle Lift's Trademark Claims and Files Countersuit 2Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 2Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 3Health News:Beauty.com Partners With Fashion Designer Jenni Kayne 4Health News:Researchers develop new tool to predict who will use microbicides 2Health News:Researchers develop new tool to predict who will use microbicides 3Health News:Spiritual Health Experts Speak at Chaplains Conference in Pittsburgh March 8-12 2Health News:Benefitfocus(R) Healthcare Video Portal Merges Community with Credibility 2Health News:Gender differences in language appear biological 2Health News:Gender differences in language appear biological 3
... biocompatible, flexible, one-piece artificial cornea (keratoprosthesis) designed ... cornea., ,The World Health Organisation (WHO) reports ... million people worldwide, however only 100,000 people ... is due to a combination of inadequate ...
A comprehensive CPT surgical, radiological and anesthesia coding reference....
PDA-version of the leading portable drug reference....
PDA format of the well-known standard antimicrobial reference....
Medicine Products: